Navigation Links
Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
Date:10/19/2010

international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at Kellogg and other business schools in the area of entrepreneurship.

"I am honored and excited to be asked to join the Board of Aethlon Medical. In my 30+ years of experience in the area of blood purification therapies, I have rarely seen an extracorporeal device that has the breadth of market opportunities that are engendered by the Aethlon Hemopurifier®. Firstly, it represents the most logical solution as a countermeasure to a bioterror attack owing to its expected efficacy regardless of any genetic manipulations that may have been engineered into a bioweapon to render vaccines impotent. Furthermore, it has a long shelf life and can be ready to deploy at a moment's notice.

"Secondly, it promises to be a highly contributing adjunct to drug therapy for a variety of chronic viral diseases such as hepatitis C and HIV that may well significantly increase the percentage of patients achieving a non-detectable viral load status. Thirdly, it has the potential to be a front-line therapy against pandemic viral outbreaks particularly in cases where vaccines do not exist or are ineffective.

"Lastly, the Hemopurifier's ability to adsorb exosomes, the small particles that are released by solid tumors to provide localized immunity by inactivating the host's cellular immune defenses, represents a major opportunity in the cancer arena.

"Consequently, I look forward with great anticipation to working with the Aethlon Board and its employees to capitalize on this wealth of opportunities in the coming years," stated Kenley.

Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from the Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg Graduate School of Management, als
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... SANTA MONICA, Calif. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... who is at the White House today for National ... Proposition 46 that consumer advocates released today. Consumer advocates ... woman who spoke out after losing her ... later discovering that the doctor had a history of ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major ... product a mere 8 months after company startup. Its ... glycan release enzyme used in the “Biologics” industry for ... for tissue pathology on Mass Spec devices. PRIME™ is ... North American market (PNGase F PRIMETM). N-Zyme is ...
(Date:9/17/2014)... Recently, BambooIndustry.com, an outstanding company in the ... floorings . There are more than 1000 items in this ... big promotion for these useful items. Each of them is ... , “We are very proud to unveil the new ... these items are made with natural materials by experienced workers. ...
(Date:9/17/2014)... 18, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has released its 2014 ... the firm has launched a big sale for these ... available at deeply discounted rates, from 15 to 65 ... company insists on using comfortable to wear materials. Its ...
(Date:9/17/2014)... September 18, 2014 Dr. Shalev is a ... to Houston to study at the University of Texas, and ... studying she realized her real passion lay in dentistry, and ... from the University of Texas Health Science Center at Houston ... and is a member of The Greater Houston Dental Society, ...
(Date:9/17/2014)... 18, 2014 The National Resident Matching ... , a comprehensive analysis of the relationship between unique ... specialty. The new edition is based on the ... for U.S. allopathic medical school senior students and all ... able to provide this new edition of Charting Outcomes ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3
... 5 (HealthDay News) -- Giving antibiotics to pregnant women at ... newborns, according to a new study. Use of antibiotics ... and should also be used in developing countries, at least ... Edmond, of the London School of Hygiene and Tropical Medicine ...
... WASHINGTONThe rezoning around a planned light rail line in the ... the health of the people in the communities it would ... today by PolicyLink, TakeAction Minnesota, and ISAIAH, a nonprofit coalition ... Paul and St. Cloud region. The HIA was made possible ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
... HealthDay Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- ... United States in recent years are charted in a new report. ... by 1.8 percent a year in men and 1.6 percent a ... And from 1990 through 2008, death rates plunged almost 23 percent ...
... quality of life higher in cancer survivors who exercise, ... though most doctors recommend exercise, many patients fail ... University of Colorado Cancer Center, recently published in the ... by the American College of Sports Medicine, makes planning ...
... The rotovirus vaccine was pulled from the marketplace in ... the updated rotavirus vaccines do not appear to increase ... to a new study by child health experts at ... of the vaccine,re-introduced in 2006 and 2008, prevent infection ...
Cached Medicine News:Health News:Antibiotics in Pregnancy May Shield Newborns From Strep B 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Downloadable tool helps cancer survivors plan and monitor exercise 2Health News:U-M study shows updated rotavirus vaccine not linked to increase in bowel obstruction 2